- Home
- CUE vs CODA Comparison
CUE vs CODA Comparison
Compare CUE & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- CODA
- Stock Information
- Founded
- CUE 2014
- CODA 1994
- Country
- CUE United States
- CODA United States
- Employees
- CUE N/A
- CODA N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- CODA Industrial Machinery/Components
- Sector
- CUE Health Care
- CODA Industrials
- Exchange
- CUE Nasdaq
- CODA Nasdaq
- Market Cap
- CUE 48.0M
- CODA 88.7M
- IPO Year
- CUE 2018
- CODA N/A
- Fundamental
- Price
- CUE $0.74
- CODA $8.10
- Analyst Decision
- CUE Strong Buy
- CODA Strong Buy
- Analyst Count
- CUE 3
- CODA 1
- Target Price
- CUE $3.00
- CODA $11.00
- AVG Volume (30 Days)
- CUE 323.3K
- CODA 59.6K
- Earning Date
- CUE 08-13-2025
- CODA 06-16-2025
- Dividend Yield
- CUE N/A
- CODA N/A
- EPS Growth
- CUE N/A
- CODA 21.86
- EPS
- CUE N/A
- CODA 0.30
- Revenue
- CUE $7,991,000.00
- CODA $22,758,966.00
- Revenue This Year
- CUE N/A
- CODA $11.64
- Revenue Next Year
- CUE $23.84
- CODA $14.53
- P/E Ratio
- CUE N/A
- CODA $26.83
- Revenue Growth
- CUE 13.83
- CODA 24.78
- 52 Week Low
- CUE $0.45
- CODA $5.76
- 52 Week High
- CUE $1.99
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- CUE 51.10
- CODA 57.37
- Support Level
- CUE $0.65
- CODA $7.81
- Resistance Level
- CUE $0.83
- CODA $8.50
- Average True Range (ATR)
- CUE 0.07
- CODA 0.41
- MACD
- CUE 0.01
- CODA -0.01
- Stochastic Oscillator
- CUE 30.43
- CODA 63.45
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.